Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Antibodies with lambda light chains ( λ -antibodies) are generally considered to be less developable than those with kappa light chains ( κ -antibodies). Though this hypothesis has not been formally established, it has led to substantial systematic biases in drug discovery pipelines and thus contributed to kappa dominance amongst clinical-stage therapeutics. However, the identification of increasing numbers of epitopes preferentially engaged by λ -antibodies shows there is a functional cost to neglecting to consider them as potential lead candidates. Here, we update our Therapeutic Antibody Profiler (TAP) tool to use the latest data and machine learning-based structure prediction, and apply it to evaluate developability risk profiles for κ -antibodies and λ -antibodies based on their surface physicochemical properties. We find that while human λ -antibodies on average have a higher risk of developability issues than κ -antibodies, a sizeable proportion are assigned lower-risk profiles by TAP and should represent more tractable candidates for therapeutic development. Through a comparative analysis of the low- and high-risk populations, we highlight opportunities for strategic design that TAP suggests would enrich for more developable λ -antibodies. Overall, we provide context to the differing developability of κ - and λ -antibodies, enabling a rational approach to incorporate more diversity into the initial pool of immunotherapeutic candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein complex prediction with AlphaFold-Multimer
Evans, R., O’Neill, M., Pritzel, A., Antropova, N., Senior, A., Green, T., Žídek, A., Bates, R., Blackwell, S., Yim, J., et al. (2021) · doi:10.1101/2021.10.04.463034 · Cited by 3,808 · cited 2×
“We selected ABodyBuilder2 as it has been shown to outperform other antibody-speci fi c modelling methods 31 , while being competitive with AlphaFold Multimer 33 at orders of magnitude faster modelling rates.”
OpenMM 7: Rapid development of high performance algorithms for molecular dynamics
Eastman, P., Swails, J., Chodera, J. D., McGibbon, R. T., Zhao, Y., Beauchamp, K. A., Wang, L.-P., Simmonett, A. C., Harrigan, M. P., Stern, C. D., et al. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005659 · Cited by 2,748 · cited 2×
“Next, using pdb fi xer 51 , we protonated the models at a pH of 7.5, soaked them in truncated octahedral water boxes with a padding distance of 1 nm, and added sodium or chloride counter-ions to neutralise charges and then NaCl to an ionic strength of 150 mM.”
InfluentialProtein Data Bank: the single global archive for 3D macromolecular structure data
wwPDB consortium, Burley, S. K., Berman, H. M., Bhikadiya, C., Bi, C., Chen, L., Costanzo, L. D., Christie, C., Duarte, J. M., Dutta, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky949 · Cited by 1,163 · cited 2×
“In these sets a much smaller fraction of natural antibodies survived the fi ltering cut-off (~38% of Nat all versu ~75% of CST all ), likely due to the fact that natural antibodies sample longer CDRH3 lengths — which are both more conformationally diverse and harder to crystallise — as well as the general under-represe…”
SAbDab: the structural antibody database
Dunbar, J., Krawczyk, K., Leem, J., Baker, T., Fuchs, A., Georges, G., Shi, J., & Deane, C. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1043 · Cited by 674
Self-citationCoV-AbDab: the coronavirus antibody database
Raybould, M. I. J., Kovaltsuk, A., Marks, C., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa739 · Cited by 383
Self-citationFive computational developability guidelines for therapeutic antibody profiling
Raybould, M. I. J., Marks, C., Krawczyk, K., Taddese, B., Nowak, J., Lewis, A. P., Bujotzek, A., Shi, J., & Deane, C. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810576116 · Cited by 357 · cited 10×
“This result is consistent with Townsend et al. 18 and provides strong evidence that the longer CDRH3 lengths seen in λ -CSTs are due to a bias (e.g. species origin 19 ) in therapeutic development.”
InfluentialSelf-citationOlsen, T. H., Boyles, F., & Deane, C. M. (2022) · Protein Science · doi:10.1002/pro.4205 · Cited by 319
Self-citationKovaltsuk, A., Leem, J., Kelm, S., Snowden, J., Deane, C. M., & Krawczyk, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800708 · Cited by 247
Self-citationABodyBuilder: automated antibody structure prediction with data-driven accuracy estimation
Leem, J., Dunbar, J., Georges, G., Shi, J., & Deane, C. M. (2016) · mAbs · doi:10.1080/19420862.2016.1205773 · Cited by 238
Self-citationThera-SAbDab: the therapeutic structural antibody database
Raybould, M. I. J., Marks, C., Lewis, A. P., Shi, J., Bujotzek, A., Taddese, B., & Deane, C. M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz827 · Cited by 199 · cited 6×
“To assess the properties of CSTs over time, we split the set by the year they were given a proposed WHO International Non-proprietary Name, yielding 356 named between 1987 – 2017 and 308 named between 2018 and the present day.”
Influential
Cited by
Giulini, M., Schneider, C., Cutting, D., Desai, N., Deane, C. M., & Bonvin, A. M. J. J. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae583 · Cited by 41
Self-citationBashour, H., Smorodina, E., Pariset, M., Zhong, J., Akbar, R., Chernigovskaya, M., Lê Quý, K., Snapkow, I., Rawat, P., Krawczyk, K., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06561-3 · Cited by 32
Waury, K., Lelieveld, S., Abeln, S., & van den Ham, H.-J. (2025) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1013057 · Cited by 1
Metadata
- Authors
- Raybould, M. I. J., Turnbull, O. M., Suter, A., Guloglu, B., & Deane, C. M.
- Venue
- Communications Biology
- Published
- 2024-01-08
- Volume
- 7
- Issue
- 1
- Pages
- 62-62
- ISSN
- 2399-3642 (ISSN-L)
- OpenAlex
- W4390661248
- Cited by
- 42
- References
- 13
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling. https://app.cochat.ai/papers/10.1038/s42003-023-05744-8
- The paper
- Raybould, M. I. J., Turnbull, O. M., Suter, A., Guloglu, B., & Deane, C. M. (2024). Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling. Communications Biology. https://doi.org/10.1038/s42003-023-05744-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.